Acumen Pharmaceuticals (ABOS) Expected to Announce Quarterly Earnings on Monday

Acumen Pharmaceuticals (NASDAQ:ABOS) is expected to be announcing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 26, 2026 at 8:00 AM ET.

Acumen Pharmaceuticals Price Performance

Acumen Pharmaceuticals stock opened at $2.68 on Monday. The business’s 50 day simple moving average is $2.62 and its 200 day simple moving average is $2.13. Acumen Pharmaceuticals has a 12 month low of $0.86 and a 12 month high of $3.60. The company has a market cap of $162.09 million, a price-to-earnings ratio of -1.21 and a beta of 0.20. The company has a current ratio of 6.02, a quick ratio of 6.02 and a debt-to-equity ratio of 0.29.

Insiders Place Their Bets

In other Acumen Pharmaceuticals news, CEO Daniel Joseph Oconnell sold 37,755 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $1.99, for a total transaction of $75,132.45. Following the sale, the chief executive officer owned 619,982 shares of the company’s stock, valued at $1,233,764.18. The trade was a 5.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 149,818 shares of company stock valued at $285,057. 7.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Acumen Pharmaceuticals

Several hedge funds have recently made changes to their positions in ABOS. Jacobs Levy Equity Management Inc. bought a new stake in shares of Acumen Pharmaceuticals during the 3rd quarter valued at $27,000. Marex Group plc purchased a new stake in Acumen Pharmaceuticals during the 2nd quarter worth about $39,000. Marshall Wace LLP bought a new position in Acumen Pharmaceuticals in the 4th quarter worth about $44,000. AQR Capital Management LLC purchased a new position in Acumen Pharmaceuticals during the 1st quarter valued at about $46,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Acumen Pharmaceuticals during the 4th quarter valued at about $47,000. 71.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ABOS has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research report on Friday, January 9th. BTIG Research lifted their price objective on Acumen Pharmaceuticals from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Finally, Wall Street Zen cut Acumen Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Acumen Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $7.00.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.